debt_leverage_profile
Small-cap Chinese biotech; estimated debt-to-equity below 0.5x; 20% rate rise adds ~CNY 2-5M annual interest expense, manageable but margin-compressive
Inferred
Agent_Inference
interest_rate_sensitivity
Low absolute debt base limits rate sensitivity; 20% rate increase estimated to reduce net margin by 1-3 percentage points given thin biotech margins
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Tibet/Qinghai high-altitude Cordyceps harvest zones (climate/access risk) and Sichuan processing corridor (logistics chokepoint)
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; primary markets are domestic China with nascent Hong Kong/Southeast Asia exposure; CNY devaluation risk is inverted (cost base in CNY)
Inferred
Agent_Inference
geographic_footprint
~90% revenue concentrated in mainland China; limited sovereign currency devaluation exposure; Hong Kong and Southeast Asia represent sub-10% combined
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Wild Cordyceps sinensis harvesters in Tibet/Qinghai likely represent >30% of raw material input; no substitutable synthetic alternative at scale currently
Inferred
Agent_Inference
business_model_type_primary
Traditional biotech/nutraceutical; minimal cloud infrastructure dependency; operations are cultivation, processing, and distribution — not SaaS-dependent
Inferred
Agent_Inference
business_model_type_secondary
ERP and e-commerce platforms (Alibaba/JD) support sales; 30-day termination of cloud services would disrupt online sales but not core manufacturing
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; business relies on physical supply chain and retail distribution, not software API integrations
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue from tangible product sales (Cordyceps supplements/health products), not investment contracts or token-based instruments
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Primarily domestic Chinese operations; GDPR/CCPA exposure minimal; subject to China PIPL data regulations for e-commerce customer data
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; fragmented Cordyceps market with many producers; no dominant market share position warranting regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (~80-85%); repeat consumer purchases provide de facto recurring revenue but no formal subscription contracts
Inferred
Agent_Inference
monetization_vector
Product sales of Cordyceps-based health supplements, nutraceuticals, and TCM ingredients through retail, e-commerce, and B2B channels
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing typical for TCM sector; wild Cordyceps scarcity supports premium pricing but cultivated substitutes cap upside; vulnerable to harvest-cost spikes
Inferred
Agent_Inference
pricing_power_rating
Moderate; premium wild Cordyceps commands brand premium, but cultivated competition and private-label pressure limit sustained pricing power — rated 5/10
Inferred
Agent_Inference
target_gross_margin_bracket
Estimated gross margin 35-50%; wild Cordyceps raw material costs are high and volatile, compressing margins relative to synthetic nutraceuticals
Inferred
Agent_Inference
churn_vulnerability_index
Low free-rider risk; physical product with no digital public-good component; repeat purchase loyalty moderate but not contractually locked
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is semi-linear to headcount; harvesting and processing are labor-intensive; doubling revenue requires ~60-70% headcount increase
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost of growth; physical cultivation, harvesting, QC, and distribution scale linearly; limited operating leverage without automation investment
Inferred
Agent_Inference
franchise_compliance_risk
No franchise network identified; direct and distributor sales model; distributor quality control drift is a risk but not classic franchise compliance exposure
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC rises significantly due to limited premium TCM consumer pool; estimated LTV/CAC ratio of 3-4x current scale compresses to ~2x
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; product value does not increase with user base; brand reputation is the primary defensible moat
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core harvesting/cultivation; AI could optimize e-commerce and logistics but cannot replace biological cultivation processes
Inferred
Agent_Inference
recession_resistance_tier
Moderate recession resistance; premium health supplements face trading-down risk; TCM/Cordyceps has cultural demand stickiness in China — Tier 2 resilience
Inferred
Agent_Inference
customer_segment_primary
Chinese middle-to-upper-class health-conscious consumers aged 35-65 purchasing premium TCM and nutraceutical products
Inferred
Agent_Inference
customer_segment_secondary
B2B pharmaceutical and health product manufacturers sourcing Cordyceps as ingredient; potential customer concentration if top 3 B2B buyers exceed 40% of revenue
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocation appears maintenance-oriented; limited evidence of large-scale capex shift to future-state automation or biotech R&D infrastructure
Inferred
Agent_Inference
sec_cik
0001885680
High
SEC-EDGAR
ticker
RAJAF
High
SEC-EDGAR